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Background: Glucosamine is commonly prescribed as a disease modulating agent in osteoarthritis. However, the
evidence to date suggests that it has a limited impact on the clinical symptoms of the disease including joint pain,
radiological progression, function and quality of life. The aim of this study was to examine the prescribing patterns
of glucosamine from 2002–2011 in an elderly Irish national population cohort using data from the Health Service
Executive Primary Care Reimbursement (HSE-PCRS) General medical services (GMS) Scheme.
Methods: Patients aged≥ 70 years on the HSE-PCRS pharmacy claims database between January 2002 and December
2011 were included. ATC code M01AX05 (glucosamine) was extracted. Prevalence rates per 1000 eligible population
with 95% confidence intervals were calculated for all years and age groups (70–74 years, ≥75 years). A negative
binomial regression analysis was used to determine longitudinal usage trends and compare prevalence rates
across years, sex and age groups.
Results: The annual patient rate of glucosamine prescribing increased significantly from 13.0/1000 eligible
population (95% CI 12.6-13.4) in 2002 to 68.7/1000 population (95% CI 67.8-69.5) in 2009 before decreasing to
62.4/1000 population (95% CI 61.6-63.2) in 2011. The rate of prescribing of glucosamine varied with sex, with
women receiving significantly more prescriptions than men. The cost of glucosamine also increased from 2002–2008.
In 2008 total expenditure reached a high of €4.6 million before decreasing to €2.6 million in 2011.
Conclusion: The national trend in prescribing of glucosamine increased significantly from 2002 to 2009 before
decreasing in 2010 and 2011, in keeping with current international guidelines. There is a need for awareness among
healthcare professionals and patients alike of the best available evidence to inform decision making relating to the
prescription and consumption of such supplements.
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Arthritis affects approximately 714,000 people in Ireland,
accounting for one in three visits to general practitioners
(GPs) [1]. Osteoarthritis (OA) is the most common form
of arthritis and is the leading cause of disability in the
elderly [2]. The prevalence of OA is expected to increase
in the coming years as risk factors, such as an ageing
population and obesity become more prevalent [3]. OA
accounts for considerable clinical and economic burden
as a result of reduced quality of life, increased use of
health care resources and loss of productivity [4]. Non-* Correspondence: rosegalvin@rcsi.ie
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reproduction in any medium, provided the orpharmacological therapy is considered to be the foundation
for the successful management of OA and consists of
individualised patient specific programmes incorporating
elements of dietary advice, physiotherapy, exercise and
patient education. Pharmacological options include the
prescription of analgesics and non steroidal anti-inflam-
matory drugs to provide pain relief but the adverse cardio-
vascular and gastrointestinal events associated with long
term use have led healthcare professionals to consider
other options [5].
For the past number of years, the cartilage constituents
such as glucosamine and chondroitin have been used as
disease modulating agents [2,3]. Glucosamine is an amino
sugar, and an important precursor in the biochemical
synthesis of glycosaminoglycans, which are part of thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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block for cartilage [3,6,7]. It is hypothesised that the oral
administration of these substances may prevent further
damage to joints that have experienced cartilage degen-
eration. The efficacy and safety of glucosamine and
chondroitin alone or in combination versus placebo with
respect to clinical symptoms, function, quality of life
and ability to modify structural changes of OA has
been examined extensively. Three systematic reviews with
meta-analysis failed to demonstrate that glucosamine and
chondroitin (or a combination of the two) had an impact
on progression of OA [3,5,8], in terms of joint pain,
radiological progression of the disease, function and
quality of life. In 2008, the UK National Institute for
Clinical Excellence (NICE) produced guidelines stipulating
that ‘the use of glucosamine or chondroitin products is
not recommended for the treatment of osteoarthritis’ [9].
These were followed by similar recommendations in
clinical guidelines on the treatment of OA of the knee
from the American Academy of Orthopaedic Surgeons
in 2010 [10]. However, in spite of scientific evidence
demonstrating little or no benefit of glucosamine sulphate
over placebo, there continues to be a growth in their use
with global sales of glucosamine reaching almost €1.47
billion in 2009 [11]. It is anticipated that sales will continue
to grow, with a forecasted increase in sales to €1.7 billion
in 2013. In the Irish context, cartilage constituents are
available as over-the-counter supplements and on pre-
scription. Until recently, glucosamine was available free
on prescription to people aged ≥ 70 years as part of the
National Shared Services Primary Care Reimbursement
Service of the Health Service Executive in Ireland (HSE-
PCRS) general medical services (GMS) scheme. Chondro-
itin is not available for reimbursement under this scheme.
The aim of this study is to examine the prescribing patterns
of glucosamine over a ten year period from 2002–2011
in an elderly Irish national population using data from
the HSE-PCRS pharmacy claims database. A secondary
objective of the study is to identify the cost of prescribing
of glucosamine to the State.
Methods
Study population and data source
This was a national cohort study of patients aged ≥ 70 years
between January 2002 and December 2011. The HSE-
PCRS general medical services scheme provides free
health services including medications to eligible persons
in Ireland. The scheme was means tested for those
aged <70 years and free for those aged ≥70 years between
July 2001 and December 2008 and over 97% of this age
group availed of the scheme nationally during this time
[12,13]. From January 2009 the Irish government removed
the ‘automatic’ entitlement to a free health services for
persons ≥ 70 years and there is now a requirement thatpeople ≥ 70 years satisfy a means test to receive free health
services. However, approximately 95% of people ≥ 70 years
are still entitled to free health services under the revised
scheme [14].
The HSE-PCRS pharmacy claims database of dispensed
medications was used to identify the study population.
The pharmacy claims database provides details on monthly
dispensed medications for each individual within the
scheme. Prescriptions are coded using the World Health
Organization Anatomical Therapeutic Chemical (ATC)
classification system [15]. Prescriber information, defined
daily doses (DDD), strength, quantity, method and unit of
administration of each drug dispensed, net ingredient cost
and pharmacist dispensing fee per item dispensed are also
available. No information on diagnosis or disease condition
is available but prescriptions of glucosamine were used as
proxies for diagnosis of OA. This method has been used in
previous studies of this nature [12,13].
Ethical approval
Permission was given by the data controller to use the
GMS dataset if anonymised and analysed at group level.
Therefore it was unnecessary to seek specific ethical
approval.
Definitions and inclusion criteria
Patients aged ≥ 70 years on the HSE-PCRS database be-
tween January 2002 and December 2011 were included
in this study. For the purposes of this study, ATC code
M01AX05 (glucosamine) was extracted. We defined long
term users as those who were prescribed glucosamine for
six or more consecutive months during the study period.
Short term users were defined as people with a dispensing
pattern that did not meet the definition for long term use
i.e. less than six consecutive months. These definitions are
consistent with those used in a previous large randomised
controlled trial that examined the impact of glucosamine
and chondroitin in people with OA [16]. A six month his-
tory of the prescribing pattern of glucosamine was ascer-
tained individuals who received a glucosamine prescription
in January 2002 to establish prescribing history.
Statistical analysis
Prevalence rates per 1000 GMS population and associated
95% confidence intervals for individuals aged≥ 70 years were
calculated as a proportion of all eligible persons (≥ 70 years)
entitled to free health services, as identified from the annual
reports produced by the PCRS. Prevalence rates of glucosa-
mine prescribing and 95% confidence intervals were also
calculated across years, age groups (70–74 years, ≥75 years)
and sex. A negative binomial regression model was used
to determine trends in prescribing rates. The log of the
GMS population was used as the offset term and year,
age group, sex and all possible interactions between
Figure 1 Prevalence rate (per 1000 population) of glucosamine
prescribing and 95% confidence intervals (CI) for 2002 -2011.
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annual costs were calculated as the total expenditure which
includes the net ingredient cost of the drug, value added
tax and pharmacist dispensing fee. The data were analysed
using Stata version 11 (StataCorp, College Station, Tx,
USA) and SAS version 9.3 (SAS Institute Inc. Cary, NC,
USA). The Bonferroni method was used to adjust for
multiple comparisons and p-values <0.05 were deemed
significant.
Results
Descriptive statistics
From January 2002 to December 2011, the number of
individuals aged ≥70 years identified from the Irish HSE-
Primary Care Reimbursement Services (PCRS) pharmacy
database and the PCRS annual reports that are entitled to
free healthcare range from 309,330 and 351,853 with a
mean of 334, 249 (SD 15,787) individuals identified per
year. On average 58% of the study population are female
and 42% are male.
Prescribing trends of glucosamine
Each year during the study period, between 4,126 and
23,308 people ≥70 years were prescribed glucosamine on
at least one occasion. Table 1 displays the prevalence rate
of glucosamine prescribing (per 1000 population) over
the study period. In 2002, 13.0/1000 population (95% CI
12.6-13.4) received at least one glucosamine prescription.
This figure increased to 68.7/1000 population (95% CI
67.8-69.5) in 2009 before decreasing to 62.4/1000 popula-
tion (61.6-63.2) in 2011. On average 69% of individuals
who were prescribed glucosamine between 2002 and 2008
were defined as long term users and this decreased to 65%
between 2009 and 2011. Figures 1 and 2 also illustrate
the overall prevalence rate trends in prescribing (Figure 1)
and trends by age and sex (Figure 2) during the study
period.Table 1 Prevalence rate (per 1000 population) of
glucosamine prescribing and 95% confidence intervals
(CI) for 2002 - 2011
Year Prevalence rate (95% CI)
2002 13.0 (12.6-13.4)
2003 22.7 (22.2-23.3)
2004 31.4 (30.8-32.0)
2005 39.4 (38.7-40.1)
2006 47.4 (46.6-48.1)
2007 54.4 (53.6-55.2)
2008 60.5 (59.7-61.3)
2009 68.7 (67.8-69.5)
2010 67.4 (66.5-68.2)
2011 62.4 (61.6-63.2)Sex and age differences
Table 2 shows the prevalence rates and 95% confidence
intervals for both sexes and age groups for each year of
the study. The fixed term, sex × age group × year, was
significant in the model (p = 0.0004) and hence, by the
hierarchical principle, all lower order terms involving
these variables (sex, age group, year, sex × age group,
sex × year and age group × sex) were included in the
model. The estimated differences in prevalence of glucosa-
mine between the males and females from the model for
both age groups and for all years were calculated. Signifi-
cant differences in prevalence rates of glucosamine were
observed for males and females for both age groups for all
years, with one exception. In 2007, there was no signifi-
cant difference in the prevalence between males in the
70–74 age group and males in the ≥ 75 age group. Females,
for both age groups, were significantly more likely to
receive a glucosamine prescription than males and
additionally males and females in the 70–74 year age
group were significantly more likely to receive a glucosa-
mine prescription than in the ≥ 75 age group.
Cost
The cost of glucosamine prescribing during the study
period is displayed in Table 3. The net ingredient cost of
glucosamine increased from €419,497 in 2002 to almost
€4 million in 2008. Costs started to decrease in 2009
and were approximately €1.9 million in 2011. The total
expenditure rose from €457,378 in 2002 to over €4.6
million in 2008 before decreasing to just under €2.6 million
in 2011.
Discussion
Principal findings
The findings from this national population based study
indicate that the overall rate of glucosamine prescribing
in individuals ≥ 70 years increased significantly between
2002 to 2009 before decreasing in 2010 and 2011. The
decrease in prescribing trends in recent years is in keep-
ing with the 2008 NICE guidelines where the use of
Figure 2 Prevalence rate (per 1000 population) and 95% confidence intervals (CI) of glucosamine prescribing for males and females
for two age groups (70-74 years and ≥ 75 years) from 2002 to 2011.
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mended for the treatment of osteoarthritis [9]. The rate of
prescribing of glucosamine varies with sex, with women
receiving significantly more prescriptions than men. Our
results also indicate that a significant cohort of patients
receive glucosamine on a long term basis.
Results in the context of current literature
The prevalence and pattern of glucosamine consumption
is of significance for public health and future health pro-
motion due to the rise in the elderly population, increasing
consumer interest in the value of healthy diet and exercise
and growth in public awareness of the importance of pre-
ventive health [17]. While prescribing trends have reduced
in Ireland in the years following the introduction of the
NICE guidelines in 2008, our results indicate that over 6%
of individuals over 70 years were prescribed glucosamine
in 2011. Similar patterns are evident in the UK whereTable 2 Prevalence rate and 95% confidence intervals (CI) of
age groups (70–74 years and ≥ 75 years) from 2002 to 2011
Year Prevalen
Males (95% CI)
70-74 years ≥ 75 years
2002 11.1 (10.5-11.6) 8.0 (7.6-8.4)
2003 18.9 (18.3-19.5) 14.2 (13.7-14.7)
2004 25.1 (24.3-25.9) 20.5 (19.9-21.2)
2005 32.8 (32.0-33.5 25.4 (24.7-26.1)
2006 38.1 (37.2-38.9) 32.3 (31.5-33.1)
2007 43.9 (43.0-44.8) 37.8 (36.9-38.6)
2008 49.1 (48.2-50.1) 41.0 (40.1-41.9)
2009 58.7 (56.8-60.7) 46.3 (45.0-47.7)
2010 58.0 (56.1-60.0) 44.3 (42.9-45.6)
2011 47.3 (45.7-49.0) 43.3 (42.0-44.7)prescribing trends have also dropped, yet the net ingredi-
ent cost of glucosamine was over £7 million in 2011
[18]. The lag between evidence availability and uptake
by clinicians has been examined and findings from a
systematic review suggest that there are a number of
barriers to guideline uptake in the primary care. A number
of reasons cited by GPs’ for not adhering to clinical guide-
lines included the robustness of evidence supporting
the guideline, GPs’ clinical experience at odds with the
guideline recommendation, professional responsibility
to the patient, practical issues with guideline uptake and
guideline format [19]. A combination of these factors may
have contributed to the delay in the uptake of the guide-
lines in the treatment of OA. However, the totality of
evidence demonstrates that there are no clinically meaning-
ful effects of chondroitin, glucosamine or their combination
on perceived joint pain or joint space narrowing in indi-
viduals who have OA [3]. In light of this recent evidenceglucosamine prescribing for males and females for two
ce rate (per 1000 population)
Females (95% CI)
70-74 years ≥ 75 years
21.0 (20.4-21.7) 13.1 (12.6-13.6)
35.8 (35.0-36.6) 23.3 (22.7-24.0)
50.0 (49.0-50.9) 31.9 (31.1-32.6)
64.1 (63.1-65.2) 39.5 (38.6-40.3)
73.6 (72.4-74.7) 48.6 (47.6-49.5)
83.1 (81.9-84.3) 56.2 (55.2-57.2)
94.8 (93.5-96.1) 62.2 (61.1-63.2)
110.8 (108.3-113.3) 68.6 (67.2-69.9)
109.7 (107.2-112.2) 68.1 (66.8-69.5)
93.8 (91.6-96.0) 67.2 (65.8-68.5)
Table 3 Cost of glucosamine prescribing from 2002
to 2011
Year Net ingredient cost Total expenditure
(€) (€)
2002 419,497 457,378
2003 924,454 1,028,179
2004 1,511,438 1,697,102
2005 2,117,642 2,380,054
2006 2,733,698 3,105,582
2007 3,425,933 3,915,349
2008 3,979,162 4,624,093
2009 3,388,832 4,032,809
2010 2,462,673 3,198,501
2011 1,855,585 2,558,989
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placebo in improving symptoms in patients with OA, a
report by the Irish National Centre for Pharmacoeconomics
in Ireland concluded that ‘glucosamine sulfate (DONA™)
is not a cost effective therapy for the treatment of osteo-
arthritis in the Irish healthcare setting’ [20]. This has led
to the suspension of glucosamine from the HSE-PCRS
scheme in September 2012, meaning that GPs can no longer
prescribe glucosamine for patients at no cost.
Our results demonstrate that women are significantly
more likely to receive a prescription of glucosamine than
men. This finding concurs with the current literature
suggesting that women prefer complementary medicine
in both western and eastern countries [21,22]. In addition,
women are known to be more commonly affected by OA
than men [2]. We also found that men and women aged
70–74 years were significantly more likely to receive a
prescription than those aged ≥75 years. These results
are broadly in-keeping with a recent Australian study
that examined self-reported patterns of glucosamine use
and reported that glucosamine use is higher in those aged
60–79 years than those aged ≥80 years [17]. The study
also found that women were significantly more likely
to use the supplement, consistent with previous research
findings.
Clinical implications
In the international context, glucosamine is one of the most
commonly prescribed complementary alternative medicines
(CAM) with recent research identifying 20% of the US
adult population using glucosamine [23]. In Australia,
glucosamine is the most frequently recommended CAM
by GPs and community pharmacists, with 85.2% of GPs
and 94.7% of Australian community pharmacists recom-
mending glucosamine to patients [17]. Previous studies of
consumer decision-making related to CAM have reported
that recommendations of trusted individuals such as healthcare providers and family and friends appear to play a
significant role in non-prescription decision-making [24].
A recent study examined the extent to which the level
of scientific evidence supporting the efficacy of CAM
impacts consumer decision-making in the self-selection
of these products [25]. The authors reported that a small
number of participants used direct scientific evidence
sources in the decision-making process. However, the
majority obtained knowledge of scientific evidence through
indirect sources including health care professionals and
the media. In the primary care setting, GPs, pharmacists
and physiotherapists frequently engage with patients in
the management of musculoskeletal conditions, including
OA. Therefore, it is imperative that these clinicians have
the skills to critically evaluate the quality and validity of
external scientific evidence to inform decision-making
relating to patient care.
Strengths and weaknesses of the study
The findings of this study are nationally representative for
older adults in Ireland. To our knowledge, no other study
examining national prescribing trends of cartilage constitu-
ents in an older population have been publised to date.
Our findings may represent an underestimate of the true
prevalence of consumption as cartilage constituents such
as glucosamine and chondroitin are available as over the
counter supplements. However, it is unlikely that patients
bought glucosamine over the counter during the study
period when it was possible to obain them for free under
the GMS scheme. Finally, we have used a prescription of
glucosamine as a proxy for OA as the HSE-PCRS database
does not contain information on disease status. While it is
unlikely that individuals received this product for another
condition, it may be that some high risk patients were
prescribed glucosamine as preventive therapy for OA.
Future research directions
This study highlights that the national trend in prescribing
of glucosamine increased significantly from 2002 to 2009
before decreasing in 2010 and 2011, in keeping with
current international guidelines. In the broader context of
prescribing both pharmacological and non-pharmacological
interventions, the nature and content of interactions
between patients and heath care professionals regarding
the evidence around the effectiveness of treatments need
to be considered in greater detail. In addition, there is a
need to identify and develop effective knowledge translation
strategies to convey scientific evidence to the lay audience
in ways they find personally meaningful.
Conclusion
This national elderly population based study indicates
that the trend in prescribing of glucosamine increased
significantly between 2002 and 2009 before beginning to
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guidelines. It is important that healthcare professionals
and patients alike are aware of the best available evidence
to inform decision making relating to the prescription and
consumption of glucosamine.
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